(Q36018992)

11 August 2017

1 reference

title

Fighting cancer with vaccinia virus: teaching new tricks to an old dog. (English)

1 reference

11 August 2017

vaccinia virus

1 reference

Yuqiao Shen

1

1 reference

11 August 2017

John Nemunaitis

series ordinal

2

1 reference

11 August 2017

publication date

1 February 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

11

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

180-195

1 reference

MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

CTL immunity and cytokine regulation in viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Targeted adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Edward Jenner's Inquiry; a bicentenary analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus-encoded elF-2α homolog abrogates the antiviral effect of interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Low-dose vaccinia virus-mediated cytokine gene therapy of glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Strategies to adapt adenoviral vectors for targeted delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

The development of vaccinia virus in Earle's L strain cells as examined by electron microscopy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Structure of vaccinia virus early promoters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Structure of vaccinia virus late promoters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Cidofovir in the treatment of poxvirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Cancer vaccines and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Biogenesis of vaccinia: Specific inhibition of rapidly labeled host DNA in vaccinia inoculated cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Immunization of Patients with Malignant Melanoma with Autologous CD34+ Cell-Derived Dendritic Cells Transduced Ex Vivo with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Public health. Treating vaccine reactions: two lifelines, but no guarantees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Early virus protein synthesis in vaccinia virus-infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Smallpox vaccination: a review, part II. Adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Danger signals: SOS to the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Movements of vaccinia virus intracellular enveloped virions with GFP tagged to the F13L envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

The complete DNA sequence of vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia as a vector for gene delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Immunodeficiency and cancer: prospects for correction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Remission of chronic lymphocytic leukemia after smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Interaction of assembled progeny pox viruses with the cellular cytoskeleton

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus utilizes microtubules for movement to the cell surface.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Prostate-specific antigen vaccines for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Viral vectors for dendritic cell-based immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

THE REPLICATION AND COATING OF VACCINIA DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Clinical protocol. Intra-Lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Overview analysis of adjuvant therapies for melanoma--a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Inhibition of the complement cascade by the major secretory protein of vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Recombinant CD63/ME491/neuroglandular/NKI/C-3 antigen inhibits growth of established tumors in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-Expressing sindbis virus replicon particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

IL-15 induces IFN-beta and iNOS gene expression, and antiviral activity of murine macrophage RAW 264.7 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Relationship between vaccinia virus intracellular cores, early mRNAs, and DNA replication sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Carcinoembryonic antigen-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

The danger model: a renewed sense of self

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Adjuvant immunotherapy for solid tumors: from promise to clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Selectively replicating viral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Efficacy of cidofovir in a murine model of disseminated progressive vaccinia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Targeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus infection disrupts microtubule organization and centrosome function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Development of effective immunotherapy for the treatment of patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Progress in human tumour immunology and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

The rate of formation of vaccinia deoxyribonucleic acid and vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Nucleotide sequence of 42 kbp of vaccinia virus strain WR from near the right inverted terminal repeat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus immune evasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

The formation and function of extracellular enveloped vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Assembly of vaccinia virus revisited: de novo membrane synthesis or acquisition from the host?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Cytotoxic T-cell induction in metastatic melanoma patients undergoing recombinant vaccinia virus-based immuno-gene therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Clinical application of dendritic cells in cancer vaccination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Intracellular and extracellular vaccinia virions enter cells by different mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus intracellular movement is associated with microtubules and independent of actin tails

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus infection disarms the mitochondrion-mediated pathway of the apoptotic cascade by modulating the permeability transition pore

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

inferred from DOI database lookup

7 January 2021

based on heuristic

Adsorption and penetration of enveloped and naked vaccinia virus particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

inferred from DOI database lookup

7 January 2021

based on heuristic

A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.10.015

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMTHE.2004.10.015

1 reference

11 August 2017

1 reference